,address1,address2,city,state,zip,country,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,The Canadian Venture Building,82 Richmond Street East,Toronto,ON,M5C 1P1,Canada,https://www.cotingapharma.com,Biotechnology,Healthcare,"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","{'maxAge': 1, 'name': 'Ms. Alison D. Silva MA, MS', 'age': 43, 'title': 'CEO, Pres & Director', 'yearBorn': 1979, 'fiscalYear': 2018, 'totalPay': 406888, 'exercisedValue': 0, 'unexercisedValue': 0}",1546214400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,30.856846,6500,6500,0,0,0,0.0,0.0,0,0,2198,1e-05,0.0001,0.0001,0.0001,0.0,0.0,USD,425766,0.0,20510687,21986400,0.08844,0.0,-0.178,1556582400,1588204800,1580428800,-2538439,-0.86,1:10,1498780800,-0.199,PNK,EQUITY,COTQF,COTQF,COTINGA PHARMACEUTICALS INC,Cotinga Pharmaceuticals Inc.,1254144600,America/New_York,EDT,-14400000,0.0001,none,46112,0.002,-2141954,469680,0.01,0.048,-1.19873,-728244,245691,-516139,0.0,0.0,0.0,CAD,
1,The Canadian Venture Building,82 Richmond Street East,Toronto,ON,M5C 1P1,Canada,https://www.cotingapharma.com,Biotechnology,Healthcare,"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","{'maxAge': 1, 'name': 'Dr. Richard T. Ho', 'age': 59, 'title': 'Chief Scientific Officer', 'yearBorn': 1963, 'fiscalYear': 2018, 'totalPay': 239097, 'exercisedValue': 0, 'unexercisedValue': 0}",1546214400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,30.856846,6500,6500,0,0,0,0.0,0.0,0,0,2198,1e-05,0.0001,0.0001,0.0001,0.0,0.0,USD,425766,0.0,20510687,21986400,0.08844,0.0,-0.178,1556582400,1588204800,1580428800,-2538439,-0.86,1:10,1498780800,-0.199,PNK,EQUITY,COTQF,COTQF,COTINGA PHARMACEUTICALS INC,Cotinga Pharmaceuticals Inc.,1254144600,America/New_York,EDT,-14400000,0.0001,none,46112,0.002,-2141954,469680,0.01,0.048,-1.19873,-728244,245691,-516139,0.0,0.0,0.0,CAD,
2,The Canadian Venture Building,82 Richmond Street East,Toronto,ON,M5C 1P1,Canada,https://www.cotingapharma.com,Biotechnology,Healthcare,"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","{'maxAge': 1, 'name': 'Mr. Victor  Hugo C.M.A., CPA', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}",1546214400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,30.856846,6500,6500,0,0,0,0.0,0.0,0,0,2198,1e-05,0.0001,0.0001,0.0001,0.0,0.0,USD,425766,0.0,20510687,21986400,0.08844,0.0,-0.178,1556582400,1588204800,1580428800,-2538439,-0.86,1:10,1498780800,-0.199,PNK,EQUITY,COTQF,COTQF,COTINGA PHARMACEUTICALS INC,Cotinga Pharmaceuticals Inc.,1254144600,America/New_York,EDT,-14400000,0.0001,none,46112,0.002,-2141954,469680,0.01,0.048,-1.19873,-728244,245691,-516139,0.0,0.0,0.0,CAD,
3,The Canadian Venture Building,82 Richmond Street East,Toronto,ON,M5C 1P1,Canada,https://www.cotingapharma.com,Biotechnology,Healthcare,"Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.","{'maxAge': 1, 'name': 'Mr. Paul  Papi', 'title': 'VP of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1546214400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,30.856846,6500,6500,0,0,0,0.0,0.0,0,0,2198,1e-05,0.0001,0.0001,0.0001,0.0,0.0,USD,425766,0.0,20510687,21986400,0.08844,0.0,-0.178,1556582400,1588204800,1580428800,-2538439,-0.86,1:10,1498780800,-0.199,PNK,EQUITY,COTQF,COTQF,COTINGA PHARMACEUTICALS INC,Cotinga Pharmaceuticals Inc.,1254144600,America/New_York,EDT,-14400000,0.0001,none,46112,0.002,-2141954,469680,0.01,0.048,-1.19873,-728244,245691,-516139,0.0,0.0,0.0,CAD,
